drugset / Trial / NCT02511184
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
Open-labelTreatment
Summary
The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.
Timeline
- Start
- 2015-10
- Primary completion
- 2017-12
- Completion
- 2017-12
Outcome
Outcome not reported
Stopped (Enrollment): “Decision based on the low enrollment mainly due to high efficacy drugs available in 1st line ALK-positive NSCLC (eg alectinib), not due to any safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.